Trial Profile

A Phase 1, Placebo-controlled, Within-Cohort Randomized, Double-blind, Single and Multiple Ascending Dose Study of the Safety, Tolerability and Pharmacokinetics of 7HP349 in Normal Healthy Male Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 25 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Alintegmod (Primary)
Indications Chagas disease; COVID 2019 infections; Influenza virus infections; Solid tumours; Tuberculosis
Focus Adverse reactions; First in man
Sponsors 7 Hills Pharma

22 May 2023 According to a 7 Hills Pharma media release, $13MM in federal grant awards, in collaboration with world-class institutions such as The Texas Heart Institute, the University of Texas MD Anderson Cancer Center, the University of Texas Health Science Center, and the Icahn School of Medicine fully funded this trial.
01 Nov 2021 Results published in the 7 Hills Pharma Media Release.
01 Nov 2021 Status changed from recruiting to completed, according to a 7 Hills Pharma media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com